Fig. 16.1 Primary cause of disease in pediatric liver transplant recipients in the United States, 2010–2012 16.2 Primary Hepatic Malignancies The primary liver tumor seen most frequently in children is…
Inclusion criteria Exclusion criteria Confirmed diagnosis of primary sclerosing cholangitis before liver transplantation Hepatic artery thrombosis or stenosis And Chronic ductopenic rejection Cholangiographic evidence of intrahepatic and/or extrahepatic biliary stricturing,…
Authors # of transplant recipients Total cases with pre-transplant malignancies # of recurrences post-transplant Type of cancer and pre-transplant time Post-transplant recurrence time Treatment Last follow-up post-recurrence Kelley et al….
Authors (references) No. of patients HBV DNA positive at LT (%) Prevention of HBV recurrence Follow-up (months) HBV recurrence N (%) Risk factors for HBV recurrence HBIG regimen Antiviral Indefinite…
Author Year n LRT Inclusion criteria for DS protocol Successful DS criteria Mandatory waiting time prior to LT (months) The role of AFP DS rate LT (patients) Waiting time to…
1. Liver transplant for autoimmune hepatitis 2. Autoantibodies (anti-nuclear, anti-smooth muscle or anti-liver kidney microsomal) in significant titer (>1:40) 3. Sustained rise (above twice normal of levels) of serum aminotransferase…
Milan criteria [5] •One lesion smaller than 5 cm •Up to three lesions smaller than 3 cm •No extrahepatic manifestations •No vascular invasion 11.2 Milan Criteria Prior to the introduction…
© Springer Science+Business Media New York 2016Paul J. Thuluvath (ed.)Disease Recurrence After Liver Transplantation10.1007/978-1-4939-2947-4_9 9. Recurrence of Metabolic Disorders After Liver Transplantation Bijan Eghtesad1, 2 and Charles Miller1, 2 (1) Department of Hepato-Pancreato-Biliary/Liver Transplantation Surgery, Cleveland…
Factor Effect on recurrent HCV References Donor Donor age Worse evolution [10, 12, 28, 32, 33] Donor steatosis Unclear [28, 34] Anti-HCV donors No influence with grafts with little or…
First author Total n; % of male % of Genotype 1 Treatment regimen Virologic response Adverse events Forns 2003 [9] 30, 83 83 Interferon alfa-2b + ribavirin for 12 weeks…
